Explore the groundbreaking insights into chordoma immunity, where multimodal profiling unveils unique immune landscapes, potentially revolutionizing personalized treatment strategies in neurosurgical oncology.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Multimodal profiling of chordoma immunity reveals distinct immune contextures.
van Oost et al., J Immunother Cancer 2024
DOI: 10.1136/jitc-2023-008138
Key Findings:
- Chordomas exhibit an “immune hot” microenvironment, with a higher immune activity compared to other sarcomas, as indicated by the Immunologic Constant of Rejection (ICR) transcriptional signature.
- Two distinct groups of chordomas were identified based on T cell infiltration, which were independent of clinical parameters.
- The group with high T cell infiltration also had high dendritic cell infiltration and multicellular immune aggregates, while the low infiltration group had lower overall immune and stromal cell densities.
- Patients with higher T cell infiltration showed more pronounced clonal enrichment of the TCR repertoire.
- The majority of chordomas maintained HLA class I expression, which is important for immune recognition.
Importance:
This comprehensive immunological characterization of chordomas provides insights into the natural immunity against these tumors. The identification of distinct immune contextures is crucial for tailoring immunotherapy treatments, potentially leading to better clinical outcomes for chordoma patients.
Contribution to Literature:
The study contributes to the understanding of chordoma immunity by using a multimodal approach, including transcriptomic profiling, imaging mass cytometry, multispectral immunofluorescence, immunohistochemical staining, and TCR profiling. It highlights the potential for personalized immunotherapy in treating chordomas based on their unique immune landscapes.